MAMark Agulnik

Mark Agulnik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Agulnik has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance

    by Allen Lin Luo, Allen Seylani, Yohannes Haile, Assal Sadighian, Sadaf Sadighian, Mark Agulnik

    Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Despite surgery and adjuvant imatinib for high-risk cases, recurrence remains high, often due to resistance from secondary kinase mutations. Imatinib is known to influence lipid metabolism in GIST and chronic myeloid leukemia (CML). This study evaluates metabolic trends in recurrent GIST post-resection to determine whether these biomarkers can signal resistance or early recurrence. Methods: This retrospective cohort study utilized de-identified data from the TriNetX database, comprising over 200 million patients across 172 healthcare systems in 18 countries. We examined total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), TG/HDL ratio, low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c, body mass index (BMI), and thyroid-stimulating hormone (TSH) in 36 patients with recurrent GIST on imatinib. Results: Thirty-six patients were included in this study. Patients underwent resection an average of 25.9 months before recurrence. Total cholesterol increased significantly (R=0.92, P=0.03), while LDL-C showed a similar increasing trend (R=0.87, P=0.050). HDL-C decreased significantly between pre- and post-recurrence periods (P=0.03). BMI differed between pre- and post-recurrence periods (P=0.047). TG showed a strong positive correlation (R=0.93, PConclusions: Patients with GIST recurrence demonstrated worsening metabolic profiles preceding recurrence—rising total cholesterol, LDL-C, TG, and BMI with declining HDL-C and TSH. Given imatinib’s usual lipid-lowering effects, reversal of this pattern may reflect emerging resistance. These metabolic biomarkers could serve as early, non-invasive indicators of recurrence and guide timely intervention.

  • Open Access

    Liver Transplantation After Prolonged Nab-Sirolimus Therapy for Unresectable Hepatic Perivascular Epithelioid Cell Tumor With Bilobar Involvement

    by Andrew John Cruz, Dylan Russell, Phillip M. Cheng, Mark Agulnik, Shefali Chopra, Mark Sturdevant, Navpreet Kaur, Jeffrey A. Kahn

    Primary hepatic perivascular epithelioid cell tumor (PEComa) is rare, and management of unresectable disease is not established. A 47-year-old woman had an 8-cm central hepatic PEComa bridging both lobes with tuberous sclerosis complex 2 alterations. She received albumin-bound sirolimus for 26 months with modest size reduction but durable stability, enabling listing with a nonstandard model for end-stage liver disease exception. She underwent right trisegment orthotopic liver transplantation, and the explant showed a well-circumscribed PEComa without vascular invasion or additional lesions. This case highlights prolonged nab-sirolimus as a bridge to transplantation in selected patients with favorable tumor biology.

  • Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial

    by Varun Monga, Scott Okuno, Brian Van Tine, Seth M Pollack, Mia Weiss, Angela Hirbe, Pedro Viveiros, Brian Schulte, Steven Attia, Brittany Siontis, et al.